📊 LIFD Key Takeaways
Is LIFD a Good Investment? Thesis Analysis
LFTD Partners is a cash-burning pharmaceutical company with severe profitability deterioration: net losses of $24.9M on $36.9M revenue (−67% margin) combined with declining top-line revenue (−1.1% YoY) and catastrophic EPS collapse (−1192% YoY). While low debt and positive operating cash flow provide temporary financial cushion, the company's inability to control operating expenses, combined with zero insider confidence, indicates structural business dysfunction that fundamentals cannot justify.
Why Buy LIFD? Key Strengths
- Strong gross margin of 34.2% indicates underlying product demand
- Positive operating and free cash flow despite net losses
- Low debt burden (0.00x debt-to-equity ratio) provides financial flexibility
LIFD Investment Risks to Consider
- Severe unprofitability: −$24.9M net loss on modest $36.9M revenue base
- Deteriorating fundamentals: declining revenue combined with exploding losses (EPS down 1192% YoY)
- Negative returns: ROE of −196.8% and ROA of −129.0% indicate capital destruction
- Liquidity concerns: quick ratio of 0.92x falls below 1.0, signaling potential working capital stress
- Zero insider activity in past 90 days suggests lack of management confidence
Key Metrics to Watch
- Operating cash flow trend and sustainability as losses mount
- Revenue stabilization and return to growth
- Operating margin expansion and path to profitability
- Insider buying activity as confidence signal
LIFD Financial Metrics
💡 AI Analyst Insight
The relatively thin 3.2% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.04x current ratio provides a solid financial cushion.
LIFD Profitability Ratios
LIFD vs Healthcare Sector
How LFTD PARTNERS INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LIFD Overvalued or Undervalued?
Based on fundamental analysis, LFTD PARTNERS INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LIFD Balance Sheet & Liquidity
LIFD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LFTD PARTNERS INC.'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.13 reflects profitable operations.
LIFD Growth Metrics (YoY)
LIFD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.7M | $62.3K | $0.00 |
| Q2 2025 | $9.5M | -$269.0K | $-0.02 |
| Q1 2025 | $9.1M | -$303.0K | $-0.02 |
| Q3 2024 | $8.7M | -$141.7K | $-0.01 |
| Q2 2024 | $9.5M | -$141.7K | $-0.04 |
| Q1 2024 | $10.7M | -$141.7K | $-0.01 |
| Q3 2023 | $11.2M | -$141.7K | $0.03 |
| Q2 2023 | $12.5M | -$141.7K | $0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LIFD Capital Allocation
LIFD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LFTD PARTNERS INC. (CIK: 0001391135)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIFD
What is the AI rating for LIFD?
LFTD PARTNERS INC. (LIFD) has an AI rating of STRONG SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIFD's key strengths?
Claude: Strong gross margin of 34.2% indicates underlying product demand. Positive operating and free cash flow despite net losses.
What are the risks of investing in LIFD?
Claude: Severe unprofitability: −$24.9M net loss on modest $36.9M revenue base. Deteriorating fundamentals: declining revenue combined with exploding losses (EPS down 1192% YoY).
What is LIFD's revenue and growth?
LFTD PARTNERS INC. reported revenue of $36.9M.
Does LIFD pay dividends?
LFTD PARTNERS INC. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find LIFD SEC filings?
Official SEC filings for LFTD PARTNERS INC. (CIK: 0001391135) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIFD's EPS?
LFTD PARTNERS INC. has a diluted EPS of $-1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIFD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LFTD PARTNERS INC. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIFD stock overvalued or undervalued?
Valuation metrics for LIFD: ROE of -196.8% (sector avg: 15%), net margin of -67.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIFD stock in 2026?
Our dual AI analysis gives LFTD PARTNERS INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIFD's free cash flow?
LFTD PARTNERS INC.'s operating cash flow is $1.3M, with capital expenditures of $121.6K. FCF margin is 3.2%.
How does LIFD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -67.3% (avg: 12%), ROE -196.8% (avg: 15%), current ratio 3.04 (avg: 2).